DETERMINATION OF OPTIMAL REVASCULARIZATION STRATEGY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS WITH MULTIVESSEL CORONARY DISEASE WITH INTERACTIVE CALCULATOR
https://doi.org/10.17802/2306-1278-2015-4-42-52
Abstract
Purpose. The purpose of this study was to create a model and interactive calculator for a differentiated choice of revascularization strategy in patients with ST-elevation myocardial infarction (STEMI) and coronary artery multivessel disease (MVD).
Material and methods. The study included 327 patients with STEMI and MVD undergoing primary percutaneous coronary intervention (PCI). Patients were divided into two groups: 1) Multivessel stenting (MS) (n=91); 2) Staged PCI (SP) (n=236). Study endpoints over 12 months were significant adverse cardiovascular events. Relative frequency of occurrence of an adverse outcome was evaluated and prognostic value for each of 12 demographic, clinical and angiographic factor was calculated for each revascularization strategy.
Results. The negative predictive value for adverse outcome in patients undergoing MS strategy had the following factors: myocardial infarction in past; severe coronary atherosclerosis (SYNTAX Score≥23); Age ≥65 years; female. Negative predictive value for SP strategy had the following factors: stroke in past; myocardial infarction in past; polyvascular atherosclerosis; three-vessel coronary artery disease; using of bare metal stents. The main result of this study was creation of interactive calculator for determine the optimal revascularization strategy for STEMI patients with MVD.
Conclusion. Using the developed model of differentiated choice of the optimal revascularization strategy and created calculator can improve treatment outcomes for STEMI patients with MVD.
About the Authors
Roman Tarasov
Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
6, Sosnoviy blvd., Kemerovo, 650002
V. I. GANYUKOV
Federal State Budgetary Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
6, Sosnoviy blvd., Kemerovo, 650002
Russian Federation
6, Sosnoviy blvd., Kemerovo, 650002
References
1. Dambrink J. H., Debrauwere J. P., van‘t Hof A. W., Ottervanger J. P., Gosselink A. T., Hoorntje J. C. et al. Nonculprit lesions detected during primary PCI: treat invasively or follow the guidelines? Eurointervention. 2010; 5: 968–975.
2. Cardarelli F., Bellasi A., Ou F. S., Shaw L. J., Veledar E., Roe M. T. et al. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am. J. Cardiol. 2009; 103: 766–771.
3. Tarasov R. S., Ganyukov V. I., Protopopov A. V., Barbarash O. L., Barbarash L. S. Six month results of randomized clinical trial: Multivessel stenting versus staged revascularization for ST-elevation myocardial infarction patients with second generation drug eluting stents. Clinical Medicine Research. 2014; 3(5): 125–129. doi: 10.11648/j.cmr.20140305.12.
4. Kushner F. G., Hand M., Smith S. C., King S. B., Anderson J. L., Antman E. M. et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With STElevation Myocardial Infarction. J. Am. Coll. Cardiol. 2009; 54: 2205–2241.
5. Aboyans V., Desormais I., Lacroix P., Salazar J., Criqui M. H., Laskar M. et al. The general prognosis of patients with peripheral artery disease differs according to the disease localization. J. Am. Coll. Cardiol. 2010; 55: 898–903.
6. Politi L., Sgura F., Rossi R., Monopoli D., Guerri E., Leuzzi C. et al. Arandomised trial of target-vessel versus multivessel revascularization in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart. 2010; 96: 662–667.
7. Shishehbor M. H., Amini R., Oliveria L. P., Singh I. M., Kelly P., Bhatt D. L. et al. Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. JACC Cardiovasc. Interv. 2008; 1: 227–232.
8. Windecker S., Kolh P., Alfonso F., Collet J. P., Cremer J., Falk V. et al. 2014 ESC/EACTS Guidelines onmyocardial revascularization. Eur. Heart J. 2014; 278: 25–27. doi:10.1093/eurheartj/ehu.
9. Wald D. S., Morris J. K., Wald N. J., Chase A. J., Edwards R. J., Hughes L. O. et al. Randomized trial of preventive angioplasty in myocardial infarction. N. Engl. J. Med. 2013; 369 (12): 1115–1123.
10. Тарасов Р. С., Ганюков В. И. Факторы летальности у больных инфарктом миокарда с элевацией сегмента ST при многососудистом поражении коронарного русла после эндоваскулярной реваскуляризации. Комплексные проблемы сердечно-сосудистых заболеваний. 2015; 1: 32–38. Tarasov R. S., Ganyukov V. I. Factors of mortality in patients with ST-segment elevation myocardial infarction and multivessel coronary diseas after endovascular revascularization. Complex Issues of Cardiovascular Diseases. 2015; 1: 32–38. [In Rus].
Review
For citations:
Tarasov R., GANYUKOV V.I. DETERMINATION OF OPTIMAL REVASCULARIZATION STRATEGY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS WITH MULTIVESSEL CORONARY DISEASE WITH INTERACTIVE CALCULATOR. Complex Issues of Cardiovascular Diseases. 2015;(4):42-52. (In Russ.) https://doi.org/10.17802/2306-1278-2015-4-42-52
Views:
561
